Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70034 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Akash Jain und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Aortic Valve, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis. Die Arbeit nennt 23 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Recently, Acurate neo2 (ACN2; Boston Scientific, US) and Sapien‐3 series (Edwards Lifesciences, US) were compared in the IDE trial failing to demonstrate non‐inferiority of ACN2. The Myval series (MyV), an alternative balloon‐expandable device, demonstrated non‐inferiority compared to Sapien‐3 and Evolut (Medtronic, US) in the LANDMARK trial. However, no direct comparison exists between ACN2 and MyV.
Aims
We aimed to compare mid‐term clinical and hemodynamic outcomes of the ACN2 and MyV transcatheter heart valves.
Methods
This multicenter retrospective analysis included patients implanted with ACN2 and MyV series devices. The primary objective was to assess 1‐year mortality and stroke rates. Secondary outcomes included technical success, mortality, stroke, residual aortic regurgitation (AR), mean aortic gradients, and new permanent pacemaker implantation (PPI) rates up to 4 years. A matched comparison adjusting for clinical and anatomical characteristics was performed and echocardiograms were centrally analyzed.
Results
A total of 545 patients (ACN2: 144; MyV: 401) from nine institutions were included. Matched technical success rates were 87.6% and 94.4%, p = 0.180 (90.3% for ACN2 and 97% for MyV; p < 0.001 in unmatched). In‐hospital matched PPI rates were 10.1% for ACN2 and 9% for MyV. At 4 years, matched residual ≥ moderate AR rates were similar (ACN2: 15.8% vs. MyV: 21.1%, p = 0.706), though ACN2 showed better mean aortic gradients (9.2 ± 4.2 vs. 13.1 ± 5.4, p = 0.001) and effective orifice area. Unmatched mortality + stroke rates were comparable but lower for ACN2 after matching (3.4% vs. 15.7%, p = 0.005). Importantly, cardiovascular mortality (3.4% for ACN2 and 5.6% for MyV, p = 0.720) and valve‐related deaths were comparable.
Conclusion
ACN2 showed superior long‐term hemodynamics and lower matched 4‐year mortality and stroke rates, though cardiovascular mortality and valve‐related deaths were comparable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, University Clinic Hospital of Valladolid, Valladolid, Spain.
- Christian Medical College, Vellore, India.
- School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
- Interventional Cardiology Unit IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Odense University Hospital, Odense, Denmark.
- Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain.
ORCID-Profile: John Jose, Matteo Montorfano, Ashok Seth, Sengottuvelu Gunasekaran, Mario García-Gómez, Clara Fernandez-Cordón, Alberto Campo, Mathias D Jorgensen, Manuel Carrasco-Moraleja, Alberto San Román, Ignacio J Amat-Santos
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Jain, A., Jose, J., Montorfano, M., Nissen, H., Martin, P., Seth, A., Stambuk, K., Gunasekaran, S., Mussayev, A., García-Gómez, M., Fernandez-Cordón, C., Campo, A., Rodriguez, M., Jorgensen, M. D., Campillo, S., Carrasco-Moraleja, M., Román, A. S., & Amat-Santos, I. J. (2025). Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70034
Vancouver
Jain A, Jose J, Montorfano M, Nissen H, Martin P, Seth A, et al. Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70034
BibTeX
@article{Jain2025,
author = {Jain, Akash and Jose, John and Montorfano, Matteo and Nissen, Henrik and Martin, Pedro and Seth, Ashok and Stambuk, Kresimir and Gunasekaran, Sengottuvelu and Mussayev, Abdurashid and García-Gómez, Mario and Fernandez-Cordón, Clara and Campo, Alberto and Rodriguez, Marcelo and Jorgensen, Mathias D and Campillo, Sofía and Carrasco-Moraleja, Manuel and Román, Alberto San and Amat-Santos, Ignacio J},
title = {Comparison of Self‐Expandable Acurate Neo‐2 and Balloon‐Expandable Myval Transcatheter Heart Valves at 4‐Year Follow‐Up},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70034}
}
EUVIMED